Clinical-grade cellular protection liquid as well as preparation method and application thereof

A protective solution and cell technology, applied in the field of biomedicine, can solve the problems of inability to meet long-distance use in different places, direct clinical use, and rapid decline in cell viability, so as to prolong the survival rate of cells and meet the long-distance use of cells in different places , the effect of maintaining cell viability

Active Publication Date: 2016-12-14
四川驰鼎盛通生物科技有限公司
View PDF5 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] At present, most of the cell therapy uses normal saline as the commonly used infusion medium. The cells cultured and expanded in vitro are injected into sodium chloride injection, with or without an appropriate amount of human serum albumin, and stored at 0-10°C. , transported to the destination; although this preservation method is simple, safe and convenient in clinical application, it can only be used for short-term preservation, and the cell viability will drop rapidly if t

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Clinical-grade cellular protection liquid as well as preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0050] Example 1

[0051] A clinical-grade cell protection solution, which contains human serum albumin injection, low-molecular dextran amino acid injection and isotonic sodium chloride injection, the distribution ratio of each component is: 7.5ml of human serum albumin injection, 3ml of Low molecular weight dextran amino acid injection and 89.5ml isotonic sodium chloride injection;

[0052] Among them, the low-molecular-weight dextran amino acid injection is preferably a compound preparation, and every 1000ml low-molecular-weight dextran amino acid injection contains water and the following components: 4.1g containing leucine, 1.8g isoleucine, 2.9g phenylpropanoid amino acid, 1.8g threonine, 2.0g valine, 0.6g tryptophan, 2.4g methionine, 3.4g glycine, 5.0g lysine, 2.2g arginine, 1.0g histidine, 60.0g dextran 40, the auxiliary material is sodium bisulfite;

[0053] The human serum albumin injection is preferably a pharmaceutical preparation, and its volume concentration of ...

Example Embodiment

[0056] Example 2

[0057] A clinical-grade cell protection solution, which contains human serum albumin injection, low-molecular dextran amino acid injection and isotonic sodium chloride injection, the proportion of each component is: 5ml of human serum albumin injection, 5ml of low-molecular Molecular dextran amino acid injection and 90ml isotonic sodium chloride injection;

[0058] Among them, the low-molecular-weight dextran amino acid injection is preferably a compound preparation, and every 1000ml low-molecular-weight dextran amino acid injection contains water and the following components: 4.1g containing leucine, 1.8g isoleucine, 2.9g phenylpropanoid amino acid, 1.8g threonine, 2.0g valine, 0.6g tryptophan, 2.4g methionine, 3.4g glycine, 5.0g lysine, 2.2g arginine, 1.0g histidine, 60.0g dextran 40, the auxiliary material is sodium bisulfite;

[0059] The human serum albumin injection is preferably a pharmaceutical preparation, and its volume concentration of human ser...

Example Embodiment

[0062] Example 3

[0063] A clinical-grade cell protection solution, which contains human serum albumin injection, low-molecular dextran amino acid injection and isotonic sodium chloride injection. The distribution ratio of each component is: 2.5ml of human serum albumin injection, 8ml of Low molecular weight dextran amino acid injection and 89.5ml isotonic sodium chloride injection;

[0064] Among them, the low-molecular-weight dextran amino acid injection is preferably a compound preparation, and every 1000ml low-molecular-weight dextran amino acid injection contains water and the following components: 4.1g containing leucine, 1.8g isoleucine, 2.9g phenylpropanoid amino acid, 1.8g threonine, 2.0g valine, 0.6g tryptophan, 2.4g methionine, 3.4g glycine, 5.0g lysine, 2.2g arginine, 1.0g histidine, 60.0g dextran 40, the auxiliary material is sodium bisulfite;

[0065] The human serum albumin injection is preferably a pharmaceutical preparation, and its volume concentration of ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to clinical-grade cellular protection liquid as well as a preparation method and application thereof. The clinical-grade cellular protection liquid contains a human serum albumin injection, a low-molecular-weight dextran and amino acid injection and an isotonic sodium chloride injection. The preparation method comprises the step of uniformly mixing the human serum albumin injection, the low-molecular-weight dextran and amino acid injection and the isotonic sodium chloride injection. Compared with the prior art, the preparation method has the advantages that a proper amount of the human serum albumin injection and a proper amount of the dextran and amino acid injection are creatively added into the isotonic sodium chloride injection, so that nutrients can be provided for cells, meanwhile, acid-base imbalance caused by cellular metabolism can be regulated, cellular damage caused due to acidosis can be relieved, the cell survival rate can be greatly increased, the cell viability can be maintained, the cell survival time is relatively long, the cells can be directly applied to clinical application, and the application is relatively safe and convenient; and the preparation method is simple, convenient and rapid.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to a cell protection liquid and its preparation method and application. Background technique [0002] As an independent living body, cells have strong vitality, proliferation and differentiation capabilities, and functional plasticity. The mechanism of cell therapy to treat diseases is mainly divided into two categories: one is the direct effect of cells, which directly uses its specific biological activity to repair damaged tissues and organs; or plays a specific / non-specific killing effect; Indirect effects, such as secretion of related factors or active molecules to regulate the proliferation and functional activities of the patient's own cells. [0003] With the advancement of society and the vigorous development of science and technology, human beings have higher expectations for the quality of life and life expectancy. It is everyone's dream to have a healthy, happy an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A01N1/02
CPCA01N1/0226
Inventor 杨燕宋丽萍张泽辛刘康肖春胡火珍薛红
Owner 四川驰鼎盛通生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap